Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy E Davidson

Showing results (251-260 of 285) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Breast Cancer Research and Treatment|November 2, 2011
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancerAditya Bardia, Erin T Arieas, Zhe Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2011
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozoleTatiana M Prowell, Amanda L Blackford, Celia Byrne, et al.
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trialBryan P Schneider, Robert J Gray, Milan Radovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2015
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199Bryan P Schneider, Lang Li, Milan Radovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Marc L Citron, Donald A Berry, Constance Cirrincione, et al.
Breast Cancer Research and Treatment|November 15, 2011
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancerMichaela J Higgins, Tatiana M Prowell, Amanda L Blackford, et al.
Pageof 29

Showing results (251-260 of 285) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Breast Cancer Research and Treatment|November 2, 2011
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancerAditya Bardia, Erin T Arieas, Zhe Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2011
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozoleTatiana M Prowell, Amanda L Blackford, Celia Byrne, et al.
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trialBryan P Schneider, Robert J Gray, Milan Radovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2015
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199Bryan P Schneider, Lang Li, Milan Radovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Marc L Citron, Donald A Berry, Constance Cirrincione, et al.
Breast Cancer Research and Treatment|November 15, 2011
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancerMichaela J Higgins, Tatiana M Prowell, Amanda L Blackford, et al.
Pageof 29